Kardam Consulting, LLC

Portfolio, M&A, and Commercial Strategy

Kardam supports portfolio and product‑selection strategy in pharmaceuticals, aligning API capabilities, CGMP capacity, and commercial priorities. The firm also provides business‑case development and diligence support for mergers and acquisitions, including asset and platform evaluations, and assists with business development and licensing, carve‑outs, and integration of generic and API assets into existing pharmaceutical manufacturing platforms.

#2 Operational Turnarounds and Efficiency

The firm advises on operational turnarounds where performance, compliance, and service levels are critical to value. Engagements include multi‑year efficiency programs, yield and cost‑of‑goods improvements, and stabilizing CGMP manufacturing and supply chain performance under sponsor or corporate ownership.

#3 API and Drug Product Manufacturing

Kardam helps evaluate and design API and finished‑dose manufacturing networks across international, multi‑site operations. Work typically addresses network rationalization, site carve‑outs, CGMP readiness, and capital allocation to improve manufacturing efficiency and resilience in generic and branded drugs and APIs.

#4 Investor and Board Advisory

Kardam serves private equity firms, lenders, and boards seeking an independent operating view on pharmaceutical, API, and CDMO/CMO platforms. Typical mandates include investment and investment‑committee (IC) support, board‑level operating reviews, leadership and organization design at the CEO/COO/CCO level, and ongoing advisory roles for sponsors and strategic acquirers.

#5 Sectors and Focus Areas

Pharmaceuticals, including oral solid, sterile, special delivery systems, and high‑potency products
Active pharmaceutical ingredients, excipients, and intermediates
Pharmaceutical supply chain and CGMP manufacturing networks
CEO, COO, and CCO‑level leadership transitions and operating model design in complex organizations